Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | GRM5 | P41594 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29922403 | 1.00 | CYP2C19 (0.68) | CYP2C19ALDH1A1HTTMAOAMAOB | |
| SCHEMBL23649534 | 0.83 | CYP2C19 (0.68) | CYP2C19ALDH1A1HTTMAOAMAOB | |
| SCHEMBL29922033 | 0.83 | CYP2C19 (0.68) | CYP2C19ALDH1A1HTTMAOAMAOB | |
| SCHEMBL4424070 | 0.79 | CYP2C19 (0.57) | CYP2C19ALDH1A1HTTMAOAMAOB | |
| SCHEMBL31668771 | 0.77 | CYP2C19 (0.40) | CYP2C19ALDH1A1HTTMAOAMAOB | |
| SCHEMBL4423963 | 0.77 | CYP2C19 (0.64) | CYP2C19ALDH1A1HTTMAOAMAOB | |
| SCHEMBL23667545 | 0.77 | CYP2C19 (0.41) | CYP2C19ALDH1A1HTTMAOAMAOB | |
| SCHEMBL24097201 | 0.76 | CYP2C19 (0.62) | CYP2C19ALDH1A1HTTMAOAMAOB | |
| SCHEMBL11644246 | 0.74 | CYP2C19 (0.60) | CYP2C19ALDH1A1HTTMAOAMAOB | |
| SCHEMBL8283812 | 0.74 | PGR (0.55) | CYP2C19ALDH1A1HTTMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12042495-B2 | MAP4K1 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2024-07-23 | — | — | US | disclosed |
| US-20230140954-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-20230140954-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-20230140954-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-11534441-B2 | MAP4K1 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2022-12-27 | — | — | US | disclosed |
| US-11534441-B2 | MAP4K1 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2022-12-27 | — | — | US | disclosed |
| EP-4090663-A1 | MAP4K1 INHIBITORS | Blueprint Medicines Corporation (US) | 2022-11-23 | — | — | EP | disclosed |
| CN-115279771-A | MAP4K1 inhibitors | 缆图药品公司 | 2022-11-01 | — | — | CN | disclosed |
| US-20220323438-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2022-10-13 | — | — | US | disclosed |
| US-20220125780-A1 | SUBSTITUTED TETRAHYDROQUINOLINONE COMPOUNDS AS ROR GAMMA MODULATORS | AURIGENE ONCOLOGY LIMITED (IN) | 2022-04-28 | — | — | US | disclosed |
| WO-2007023242-A1 | TETRAHYDROQUINOLINONES AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007023245-A1 | TETRAHYDROQUINOLINONES AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007023290-A1 | TETRAHYDROQUINOLINONES AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007023242-A1 | TETRAHYDROQUINOLINONES AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2007-03-01 | — | — | WO | disclosed |
| EP-1723116-A2 | TETRAHYDROQUINOLINONES AND THEIR USE AS ANTAGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS | Merz Pharma GmbH & Co. KGaA (DE) | 2006-11-22 | — | — | EP | disclosed |
| US-20060004001-A1 | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO., KGAA (DE) | 2006-01-05 | — | — | US | disclosed |
| US-20050288284-A1 | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-12-29 | — | — | US | disclosed |
| WO-2005082856-A2 | TETRAHYDROQUINOLINONES AND THEIR USE AS ANTAGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-09-09 | — | — | WO | disclosed |
| WO-2005082856-A2 | TETRAHYDROQUINOLINONES AND THEIR USE AS ANTAGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-09-09 | — | — | WO | disclosed |
| US-20050197361-A1 | Specific binding is extremely high; low toxicity; high degree of activity; 2-(5-m-Tolyl-thiazol-2-yl )-7,8-dihydro-6H-quinolin-5-one, acute and/or chronic neurological disorders | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11534441-B2 | MAP4K1 inhibitors | MAP4K1, MAP4K4, MAP4K2 | CYP2C19 4270/4885ALDH1A1 2194/4885HTT 2088/4885 |
| US-20220323438-A1 | MAP4K1 INHIBITORS | MAP4K1, MAP4K4, MAP4K2 | CYP2C19 4270/4885ALDH1A1 2194/4885HTT 2088/4885 |
| US-20060004001-A1 | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors | GRM1, GRM5, GRM2 | CYP2C19 2841/4885ALDH1A1 3118/4885HTT 533/4885 |
| US-20050197361-A1 | Specific binding is extremely high; low toxicity; high degree of activity; 2-(5-m-Tolyl-thiazol-2-yl )-7,8-dihydro-6H-quinolin-5-one, acute and/or chronic neurological disorders | GRM5, GRIK5, GRIN2C | CYP2C19 3013/4885ALDH1A1 1519/4885HTT 355/4885 |
| US-20230140954-A1 | MAP4K1 INHIBITORS | MAP4K1, MAP4K4, MAP4K2 | CYP2C19 4270/4885ALDH1A1 2194/4885HTT 2088/4885 |
| US-12042495-B2 | MAP4K1 inhibitors | MAP4K1, MAP4K4, MAP4K2 | CYP2C19 4270/4885ALDH1A1 2194/4885HTT 2088/4885 |
| US-20050288284-A1 | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors | GRM1, GRM5, GRM2 | CYP2C19 2683/4885ALDH1A1 3100/4885HTT 519/4885 |
| US-20220125780-A1 | SUBSTITUTED TETRAHYDROQUINOLINONE COMPOUNDS AS ROR GAMMA MODULATORS | RORC, RORA, RORB | CYP2C19 1000/4885ALDH1A1 235/4885HTT 3189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.